[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;(19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;(19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
• 化学式: C56H61N7O11
• 分子量: 1008.1
• InChiKey: MTCKYHCLZAKVLL-NMXPRWHTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.94
• 重原子数：
  74
• 可旋转键数：
  8
• 环数：
  12.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  216
• 氢给体数：
  3
• 氢受体数：
  15

文献信息

• [EN] 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA 3-PHOSPHOGLYCÉRATE DÉSHYDROGÉNASE ET LEURS UTILISATIONS
  申请人：RAZE THERAPEUTICS INC

  公开号：WO2017156165A1

  公开（公告）日：2017-09-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• [EN] IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS<br/>[FR] DERIVES D'IMIDAZOLE DESTINES AU TRAITEMENT DE TROUBLES ALLERGIQUES ET HYPERPROLIFERATIFS
  申请人：AVANIR PHARMACEUTICALS

  公开号：WO2004091610A1

  公开（公告）日：2004-10-28

  The preferred embodiments are directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. The preferred embodiments also relate to imidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. The preferred embodiments further relate to small molecules which suppress cytokines and leukocytes.

  首选实施例涉及对过敏原的IgE反应的小分子抑制剂，这些抑制剂在过敏和/或哮喘或任何IgE具有致病性的疾病的治疗中是有用的。首选实施例还涉及咪唑分子，这些分子是细胞增殖抑制剂，因此可用作抗癌剂。首选实施例还涉及抑制细胞因子和白细胞的小分子。
• [EN] 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES<br/>[FR] DÉRIVÉS DE LA 1H-IMIDAZO[4,5-C]QUINOLINONE
  申请人：NOVARTIS AG

  公开号：WO2010139731A1

  公开（公告）日：2010-12-09

  The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c] quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H- imidazo[4,5-c] quinofinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c] quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H- imidazo[4,5-c] quinolinone derivatives; and a process for the preparation of the novel 1H- imidazo[4,5-c] quinolinone derivatives.

  该发明涉及在蛋白质和/或脂质激酶依赖性疾病的治疗中使用1H-咪唑并[4,5-c]喹啉酮衍生物及其盐，并用于制备用于治疗该等疾病的药物制剂；用于治疗蛋白质和/或脂质激酶依赖性疾病的1H-咪唑并[4,5-c]喹啉酮衍生物；一种治疗上述疾病的方法，包括向温血动物，特别是人类，施用1H-咪唑并[4,5-c]喹啉酮衍生物；包括1H-咪唑并[4,5-c]喹啉酮衍生物的药物制剂，特别用于治疗蛋白质和/或脂质激酶依赖性疾病；新颖的1H-咪唑并[4,5-c]喹啉酮衍生物；以及制备新颖的1H-咪唑并[4,5-c]喹啉酮衍生物的方法。
• Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
  申请人：——

  公开号：US20040116466A1

  公开（公告）日：2004-06-17

  The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to phenyl-aza-benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. This invention further relates to small molecules which suppress cytokines and leukocytes.

  本发明涉及针对过敏原IgE反应的小分子抑制剂，该抑制剂在过敏和/或哮喘的治疗中很有用，或者在IgE是致病因素的任何疾病中也很有用。该发明还涉及苯基-氮杂苯并咪唑分子，这些分子是细胞增殖抑制剂，因此可用作抗癌药物。此外，该发明还涉及抑制细胞因子和白细胞的小分子。
• Compositions of CXCR4 inhibitors and methods of preparation and use
  申请人：X4 Pharmaceuticals, Inc.

  公开号：US10548889B1

  公开（公告）日：2020-02-04

  The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.

  本发明提供了用于治疗、预防或改善与化学因子受体（如CXCR4）相关的疾病、紊乱或状况的组合物和使用方法。